Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

ABSTRACT Background and aims: infliximab has changed the natural history of inﬂammatory bowel disease (IBD). The advent of biosimilar treatments such as CT-P13 will hopefully improve the availability of biological therapies. Data with regard to drug switching are currently limited. The objective o...

Full description

Bibliographic Details
Main Authors:	Maria-Fernanda Guerra-Veloz, Juan-María Vázquez-Morón, María Belvis-Jiménez, Héctor Pallarés-Manrique, Teresa Valdés-Delgado, Luisa Castro-Laria, Belén Maldonado-Pérez, Antonio Benítez-Roldán, Raúl Perea-Amarillo, Vicente Merino, Ángel Caunedo-Álvarez, Ángel Vilches-Arenas, Federico Argüelles-Arias
Format:	Article
Language:	English
Published:	Aran Ediciones 2018-09-01
Series:	Revista Espanola de Enfermedades Digestivas
Subjects:	Crohn's disease Ulcerative colitis Inflammatory bowel disease Biosimilar agent CT-P13 Infliximab
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018000900006&tlng=en

Similar Items

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
by: Chibuike J. Alanaeme, et al.
Published: (2022-11-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
by: Fitzgerald T, et al.
Published: (2021-01-01)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
by: Reem Kashlan, MPH, et al.
Published: (2021-02-01)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
by: Nam Hee Kim, et al.
Published: (2014-10-01)

Adenocarcinoma de recto y ano en paciente con enfermedad de Crohn tratado con infliximab Adenocarcinoma of the rectum and anus in a patient with Crohn´s disease treated with infliximab
by: J. Egea Valenzuela, et al.
Published: (2010-08-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
by: Bas J. M. Peters, et al.
Published: (2021-02-01)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
by: George Alex, et al.
Published: (2013-10-01)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
by: Aibar Aginbay, et al.
Published: (2022-11-01)

Infliximab‐induced autoimmune hepatitis requiring liver transplantation
by: Frederick Wong, et al.
Published: (2019-11-01)

Infliximab for Anoperineal Lesions in Crohn's Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses
by: Nadia Fathallah, et al.
Published: (2022-06-01)

Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante
by: M. Luna-Chadid, et al.
Published: (2004-06-01)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
by: Shuyan Li, et al.
Published: (2023-08-01)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
by: Hye-In Jung, et al.
Published: (2021-01-01)

Evaluation of a Seton Procedure Combined With Infliximab Therapy (Early vs. Late) in Perianal Fistula With Crohn Disease
by: Myunghoon Jeon, et al.
Published: (2019-10-01)

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study
by: Ping Zhu, et al.
Published: (2022-01-01)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
by: Ye Ma, et al.
Published: (2023-03-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
by: Yizhong Wang, et al.
Published: (2021-01-01)

MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
by: Jing Feng, et al.
Published: (2022-01-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
by: A. M. Lila, et al.
Published: (2018-07-01)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
by: Akihiro Koga, et al.
Published: (2018-04-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

CT-P13: design, development, and place in therapy
by: Gabbani T, et al.
Published: (2017-06-01)

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up
by: Mia Bendix, et al.
Published: (2021-03-01)

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
by: Mia Bendix, et al.
Published: (2020-11-01)

Arteritic anterior ischemic optic neuropathy (AAION) in a patient with Crohn´s disease treated with Infliximab.
by: Elisabet Martín García, et al.
Published: (2016-10-01)

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
by: Marla C. Dubinsky, et al.
Published: (2023-09-01)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019-11-01)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
by: Yiyoung Kwon, et al.
Published: (2022-09-01)

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study
by: Jose M. Huguet, et al.
Published: (2022-08-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)